MCID: LNG111
MIFTS: 56

Lung Non-Squamous Non-Small Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards integrated aliases for Lung Non-Squamous Non-Small Cell Carcinoma:

Name: Lung Non-Squamous Non-Small Cell Carcinoma 12 15
Non- Squamous Nsclc 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080521
NCIt 49 C135017

Summaries for Lung Non-Squamous Non-Small Cell Carcinoma

Disease Ontology : 12 A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.

MalaCards based summary : Lung Non-Squamous Non-Small Cell Carcinoma, also known as non- squamous nsclc, is related to exanthem and lung cancer susceptibility 3. An important gene associated with Lung Non-Squamous Non-Small Cell Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Docetaxel and Tyrosine have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lung Non-Squamous Non-Small Cell Carcinoma

Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 228)
# Related Disease Score Top Affiliating Genes
1 exanthem 28.1 VEGFA PDCD1 KRAS KDR HRAS ERBB2
2 lung cancer susceptibility 3 26.4 VEGFA ROS1 RET PDCD1 KRAS KDR
3 lung cancer 25.3 VEGFA TYMS ROS1 RET PDCD1 KRAS
4 primary cutaneous diffuse large b-cell lymphoma, leg type 10.5 PDCD1LG2 CD274
5 signet ring basal cell carcinoma 10.5 KRAS HRAS
6 signet ring lung adenocarcinoma 10.5 EML4 EGFR ALK
7 trachea carcinoma in situ 10.5 KRAS HRAS
8 cobblestone retinal degeneration 10.5 KRAS HRAS
9 primary mediastinal large b-cell lymphoma 10.5 PDCD1LG2 CD274
10 nasal cavity adenocarcinoma 10.5 KRAS HRAS
11 occipital lobe neoplasm 10.5 ROS1 EML4 ALK
12 pleomorphic carcinoma 10.4 EGFR CD274 ALK
13 hemifacial spasm 10.4 VEGFA TYMS
14 pediatric fibrosarcoma 10.4 ROS1 EML4 ALK
15 ampulla of vater neoplasm 10.4 KRAS HRAS
16 mesenchymal cell neoplasm 10.4 ROS1 EML4 ALK
17 descending colon cancer 10.4 KRAS HRAS
18 periampullary adenoma 10.4 KRAS HRAS
19 testicular lymphoma 10.4 PDCD1LG2 PDCD1 CD274
20 acneiform dermatitis 10.4 KRAS HRAS EGFR
21 myopathy, distal, 1 10.4 PDCD1LG2 PDCD1 CD274
22 transverse colon cancer 10.4 KRAS HRAS
23 appendiceal neoplasm 10.4 KRAS HRAS
24 gallbladder benign neoplasm 10.4 KRAS HRAS
25 skin papilloma 10.4 KRAS HRAS EGFR
26 respiratory system benign neoplasm 10.4 KRAS HRAS EGFR
27 myh-associated polyposis 10.3 KRAS HRAS
28 lung adenoma 10.3 KRAS HRAS EGFR
29 adenosquamous carcinoma 10.3 KRAS EGFR CD274
30 colonic benign neoplasm 10.3 KRAS HRAS EGFR
31 small cell carcinoma 10.3 KRAS EGFR CD274 ALK
32 appendix adenocarcinoma 10.3 KRAS HRAS
33 lung benign neoplasm 10.3 KRAS HRAS EGFR
34 arteriovenous malformation 10.3 VEGFA KRAS HRAS
35 type 1 diabetes mellitus 15 10.3 HRAS CTLA4
36 central nervous system hemangioma 10.3 VEGFA RET
37 inflammatory myofibroblastic tumor 10.3 ROS1 EML4 ALK
38 mucosal melanoma 10.3 VEGFA KDR CD274
39 adenocarcinoma in situ 10.3 KRAS HRAS EGFR ALK
40 adenosquamous lung carcinoma 10.3 KRAS HRAS EGFR ALK
41 uterine benign neoplasm 10.3 VEGFA KRAS HRAS
42 peritoneal mesothelioma 10.3 VEGFA EGFR CD274 ALK
43 breast angiosarcoma 10.3 VEGFA KDR
44 reproductive organ benign neoplasm 10.3 VEGFA KRAS HRAS
45 wolffian duct adenocarcinoma 10.3 KRAS HRAS
46 thymus gland disease 10.3 EGFR CTLA4 CD274
47 mucinous lung adenocarcinoma 10.2 ROS1 KRAS HRAS EGFR
48 anus cancer 10.2 KRAS HRAS EGFR CD274
49 thymus cancer 10.2 EGFR CTLA4 CD274
50 autoimmune disease of skin and connective tissue 10.2 PDCD1 CTLA4 CD274

Graphical network of the top 20 diseases related to Lung Non-Squamous Non-Small Cell Carcinoma:



Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma

Symptoms & Phenotypes for Lung Non-Squamous Non-Small Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 44)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.76 EGFR HRAS KRAS
2 Decreased viability GR00055-A-2 10.76 EGFR HRAS KRAS
3 Decreased viability GR00055-A-3 10.76 KRAS
4 Decreased viability GR00106-A-0 10.76 KRAS
5 Decreased viability GR00221-A-1 10.76 ALK EGFR KDR RET HRAS KRAS
6 Decreased viability GR00221-A-2 10.76 KDR RET FLT1 HRAS KRAS ROS1
7 Decreased viability GR00221-A-3 10.76 ERBB2 KDR HRAS
8 Decreased viability GR00221-A-4 10.76 ALK EGFR ERBB2 KDR RET
9 Decreased viability GR00249-S 10.76 ALK KDR ROS1
10 Decreased viability GR00301-A 10.76 RET KRAS
11 Decreased viability GR00342-S-1 10.76 ROS1
12 Decreased viability GR00381-A-1 10.76 KRAS
13 Decreased viability GR00402-S-2 10.76 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.87 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.87 FLT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.87 RET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.87 ERBB2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.87 ERBB2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-171 9.87 FLT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.87 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.87 CD274
23 Increased shRNA abundance (Z-score > 2) GR00366-A-187 9.87 CD274
24 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.87 ERBB2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.87 EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.87 RET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.87 RET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.87 CD274
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.87 CD274
31 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.87 FLT1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.87 ERBB2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.87 RET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.87 KDR
36 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.87 ERBB2 KDR RET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 ERBB2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.87 RET
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 CD274 EGFR ERBB2 FLT1 KDR RET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.87 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.87 EGFR
42 Decreased cell migration GR00055-A-1 9.73 ALK FLT1
43 Decreased cell migration GR00055-A-3 9.73 EGFR HRAS
44 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 FLT1 RET ROS1

MGI Mouse Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 CTLA4 DHFR EGFR ERBB2 FLT1 HRAS
2 cellular MP:0005384 10.33 CD274 DHFR EGFR ERBB2 FLT1 KDR
3 mortality/aging MP:0010768 10.33 ALK CD274 CTLA4 DHFR EGFR EML4
4 growth/size/body region MP:0005378 10.32 ALK DHFR EGFR ERBB2 FLT1 GART
5 homeostasis/metabolism MP:0005376 10.32 ALK CD274 CTLA4 DHFR EGFR ERBB2
6 hematopoietic system MP:0005397 10.31 CD274 CTLA4 DHFR EGFR FLT1 GART
7 endocrine/exocrine gland MP:0005379 10.26 ALK CTLA4 EGFR ERBB2 HRAS KRAS
8 immune system MP:0005387 10.23 CD274 CTLA4 DHFR EGFR FLT1 KDR
9 digestive/alimentary MP:0005381 10.14 CTLA4 EGFR ERBB2 HRAS KRAS MTUS1
10 integument MP:0010771 10.13 ALK CD274 CTLA4 DHFR EGFR ERBB2
11 muscle MP:0005369 10.02 DHFR EGFR ERBB2 FLT1 KDR KRAS
12 neoplasm MP:0002006 10.02 ALK EGFR ERBB2 HRAS KRAS MTUS1
13 no phenotypic analysis MP:0003012 9.91 CD274 EGFR HRAS KDR KRAS PDCD1LG2
14 normal MP:0002873 9.81 CTLA4 EGFR ERBB2 FLT1 HRAS KDR
15 respiratory system MP:0005388 9.65 ALK CTLA4 EGFR ERBB2 HRAS KDR
16 skeleton MP:0005390 9.32 ALK CD274 CTLA4 EGFR ERBB2 HRAS

Drugs & Therapeutics for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs for Lung Non-Squamous Non-Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
2
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
3
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
4
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
5
Crizotinib Approved Phase 3 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
6
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Bevacizumab Approved, Investigational Phase 3 216974-75-3
9
nivolumab Approved Phase 3 946414-94-4
10
Pembrolizumab Approved Phase 3 1374853-91-4
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Imetelstat Investigational Phase 3 868169-64-6
13 Pharmaceutical Solutions Phase 3
14 Protein Kinase Inhibitors Phase 3
15 Tubulin Modulators Phase 3
16 Antimitotic Agents Phase 3
17 Antineoplastic Agents, Immunological Phase 3
18 Endothelial Growth Factors Phase 3
19 Angiogenesis Inhibitors Phase 3
20 Albumin-Bound Paclitaxel Phase 3
21 Mitogens Phase 3
22
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
23
Motesanib diphosphate Phase 3 850649-62-6 11450633
24
Nitroglycerin Approved, Investigational Phase 2 55-63-0 4510
25
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
26
ramucirumab Approved, Investigational Phase 2 947687-13-0
27
Ceritinib Approved Phase 2 1032900-25-6
28
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
29
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
30
Promethazine Approved, Investigational Phase 2 60-87-7 4927
31
Histamine Approved, Investigational Phase 2 51-45-6 774
32
Acetaminophen Approved Phase 2 103-90-2 1983
33
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
34
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
35
Acyclovir Approved Phase 2 59277-89-3 2022
36
Methylcobalamin Approved, Investigational Phase 2 13422-55-4
37
Hydroxocobalamin Approved Phase 2 13422-51-0 15589840 11953898
38
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
39
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
40
Gemcitabine Approved Phase 2 95058-81-4 60750
41
Etoposide Approved Phase 2 33419-42-0 36462
42
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
43
Olaparib Approved Phase 2 763113-22-0 23725625
44
Ipilimumab Approved Phase 2 477202-00-9
45
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
46
leucovorin Approved Phase 2 58-05-9 6006 143
47
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
48
Osimertinib Approved Phase 1, Phase 2 1421373-65-0 71496458
49
Nintedanib Approved Phase 2 656247-17-5 56843413
50
Durvalumab Approved, Investigational Phase 2 1428935-60-7

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
2 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Recruiting NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
3 An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy Recruiting NCT03755869 Phase 4 Anlotinib
4 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Not yet recruiting NCT03778853 Phase 4 Anlotinib Hydrochloride
5 AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting Not yet recruiting NCT04413201 Phase 4 Afatinib;Osimertinib
6 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
7 Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer Unknown status NCT03700333 Phase 3 S-1 therapy;Pemetrexed therapy
8 A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC. Unknown status NCT01656551 Phase 3 Gemcitabine;Pemetrexed;Cisplatin
9 A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT01593293 Phase 3 PemCarbo;Pem only
10 Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-squamous Non Small Cell Lung Cancer (NSCLC). Completed NCT00775385 Phase 2, Phase 3 Standard Chemotherapy;Customized Treatment
11 A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF- 06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL -CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER. Completed NCT02364999 Phase 3 Bevacizumab-Pfizer;Bevacizumab-EU;Paclitaxel;Carboplatin
12 A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT00806923 Phase 3 Cisplatin;Gemcitabine;Placebo;bevacizumab [Avastin];bevacizumab [Avastin]
13 An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy Completed NCT01351415 Phase 3 Bevacizumab;Docetaxel;Erlotinib;Pemetrexed
14 International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients Completed NCT01763645 Phase 3 Bevacizumab;Paclitaxel;Carboplatin
15 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Completed NCT03134872 Phase 3 Carboplatin;Pemetrexed
16 Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00976456 Phase 3 Bevacizumab + Pemetrexed;Bevacizumab + Pemetrexed + Carboplatin
17 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib Completed NCT02691299 Phase 3 Fruquintinib;Placebo
18 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
19 A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting NCT03409614 Phase 3 REGN2810;REGN2810/chemo/ipi;Placebo
20 Efficacy and Safety of First-line MIL60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study Recruiting NCT03196986 Phase 3 MIL60;Bevacizumab
21 A Randomized, Double-blind, Multi-center, Phase III Clinical Study Assessing the Efficacy and Safety of Sintilimab ± IBI305 Combined With Pemetrexed and Cisplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (ORIENT-31) Recruiting NCT03802240 Phase 3 Sintilimab;IBI305;Pemetrexed;Cisplatin;Placebo1;Placebo2
22 Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors Recruiting NCT04154956 Phase 3 SAR408701;Docetaxel
23 Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer Recruiting NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
24 A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting NCT03952403 Phase 3 HLX10, an engineered anti-PD-1 antibody;HLX04, a bevacizumab biosimilar;Carboplatin;Pemetrexed
25 A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE Recruiting NCT03906071 Phase 3 Sitravatinib;Docetaxel
26 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 Docetaxel
27 A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11) Active, not recruiting NCT03607539 Phase 3 Sintilimab;Pemetrexed;Platinum;Placebos
28 A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50% Active, not recruiting NCT03515629 Phase 3 REGN2810/ipi;REGN2810/chemo/ipi;Pembrolizumab
29 A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin Active, not recruiting NCT02810457 Phase 3 FKB238 (bevacizumab);Avastin (bevacizumab);Paclitaxel;Carboplatin
30 Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Active, not recruiting NCT02954172 Phase 3 Bevacizumab in combination with Paclitaxel/Carboplatin;Avastin in combination with Paclitaxel/Carboplatin
31 A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT03296163 Phase 3 MB02 (Bevacizumab Biosimilar Drug);EU-approved Avastin®;Carboplatin;Paclitaxel
32 A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02367781 Phase 3 Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;Carboplatin;Nab-Paclitaxel;Pemetrexed
33 A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02366143 Phase 3 Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;Bevacizumab;Carboplatin;Paclitaxel
34 A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT02657434 Phase 3 Atezolizumab;Carboplatin;Cisplatin;Pemetrexed
35 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
36 PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS Active, not recruiting NCT01639001 Phase 3 Crizotinib;Pemetrexed/Cisplatin;Pemetrexed/Carboplatin
37 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT04181060 Phase 3 Osimertinib
38 A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Not yet recruiting NCT04325698 Phase 3 PF-06439535 (CN);Bevacizumab-EU;Paclitaxel;Carboplatin
39 International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in Combination With Pemetrexed+Cisplatin/Carboplatin Compared to Placebo in Combination With Pemetrexed+Cisplatin/Carboplatin as First-Line Treatment of Subjects With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) Not yet recruiting NCT03912389 Phase 3 Pemetrexed;Cisplatin (or carboplatin)
40 A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC Not yet recruiting NCT04416035 Phase 3 Carboplatin;Paclitaxel
41 PD-(L)1 Inhibitors With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Suspended NCT03774732 Phase 3 Anti-PD(L)-1
42 A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor Terminated NCT01377376 Phase 3 ARQ 197 and Erlotinib;Placebo and Erlotinib
43 Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy. Terminated NCT02766140 Phase 3 SHR1020 plus Docetaxel;Placebo plus Docetaxel
44 A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer. Terminated NCT00460317 Phase 3 AMG 706;placebo;paclitaxel;carboplatin
45 A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study) Terminated NCT02775006 Phase 3 Docetaxel;Erlotinib
46 Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study Terminated NCT02004184 Phase 3 maintenance pemetrexed;pemetrexed at progression
47 Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation Unknown status NCT03153358 Phase 2 Icotinib
48 An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients Unknown status NCT01623102 Phase 2 cisplatin and gemcitabine combination with Bevacizumab;Gemcitabine combined with cisplatin chemotherapy
49 A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12 Unknown status NCT01171170 Phase 2 carboplatin paclitaxel bevacizumab;Standard treatment plus nitroglycerin
50 Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT01742767 Phase 2 Cisplatinum;Pemetrexed

Search NIH Clinical Center for Lung Non-Squamous Non-Small Cell Carcinoma

Genetic Tests for Lung Non-Squamous Non-Small Cell Carcinoma

Anatomical Context for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards organs/tissues related to Lung Non-Squamous Non-Small Cell Carcinoma:

40
Lung, Brain, Testes, Endothelial, Bone, Lymph Node, Thyroid

Publications for Lung Non-Squamous Non-Small Cell Carcinoma

Articles related to Lung Non-Squamous Non-Small Cell Carcinoma:

(show top 50) (show all 349)
# Title Authors PMID Year
1
Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. 61
32428850 2020
2
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients. 61
32111518 2020
3
Screening for anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer in New Zealand. 61
31318119 2020
4
Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer. 61
32507497 2020
5
Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. 61
32508029 2020
6
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. 61
32543258 2020
7
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer. 61
32193809 2020
8
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. 61
31332704 2020
9
Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage non-small cell lung cancer. 61
32387485 2020
10
Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy. 61
30847713 2020
11
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. 61
31231786 2020
12
Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. 61
32365867 2020
13
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. 61
32353934 2020
14
Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. 61
32132059 2020
15
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer. 61
32178474 2020
16
Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer. 61
31420240 2020
17
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer. 61
31862577 2020
18
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations. 61
31829747 2020
19
Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. 61
32021302 2020
20
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis. 61
32313723 2020
21
The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. 61
31709742 2020
22
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. 61
31835042 2020
23
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. 61
31671314 2019
24
Effects of adding necitumumab to first-line chemotherapy in patients with stage IV non-small-cell lung cancer: Meta-analysis. 61
31822198 2019
25
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. 61
31752994 2019
26
Evaluation of PAP in EGFR Mutational Testing in Advanced NSCLC: a Comparative Study. 61
31710424 2019
27
New options for combination therapy for advanced non-squamous NSCLC. 61
31512526 2019
28
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). 61
31699150 2019
29
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients. 61
31493177 2019
30
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. 61
31703637 2019
31
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study. 61
31655564 2019
32
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. 61
31338773 2019
33
The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. 61
30953094 2019
34
Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. 61
31434972 2019
35
Pemetrexed Induced Life-threatening Anaphylaxis. 61
31687290 2019
36
Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. 61
31144157 2019
37
Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. 61
31186697 2019
38
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. 61
31092443 2019
39
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. 61
30421624 2019
40
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. 61
30954906 2019
41
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. 61
30975627 2019
42
AVAiLABLE NIS - AVASTIN® in lung cancer treatment in routine oncology practice in Germany. 61
31077164 2019
43
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer. 61
30926356 2019
44
Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. 61
30940113 2019
45
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC. 61
32131287 2019
46
PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC. 61
32131304 2019
47
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy. 61
30128728 2019
48
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. 61
30797489 2019
49
Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. 61
30817606 2019
50
Phase I dose escalation study of pemetrexed and concurrent thoracic radiation in elderly patients with non-squamous non-small-cell lung cancer. 61
30496584 2019

Variations for Lung Non-Squamous Non-Small Cell Carcinoma

Cosmic variations for Lung Non-Squamous Non-Small Cell Carcinoma:

9 (show top 50) (show all 17775)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM98616023 ZZEF1 lung,NS,carcinoma,small cell carcinoma c.4892G>T p.G1631V 17:4059282-4059282 9
2 COSM86240454 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 9
3 COSM86919234 ZSWIM4 lung,NS,carcinoma,small cell carcinoma c.944G>T p.R315L 19:13809152-13809152 9
4 COSM88262283 ZRSR2 lung,NS,carcinoma,small cell carcinoma c.1180G>A p.E394K 23:15822973-15822973 9
5 COSM97720347 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 9
6 COSM137165710 ZP2 lung,NS,carcinoma,small cell carcinoma c.1608C>T p.P536= 16:21201455-21201455 9
7 COSM91416826 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 9
8 COSM149927805 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 9
9 COSM92021621 ZNF804B lung,NS,carcinoma,small cell carcinoma c.522C>A p.P174= 7:89333504-89333504 9
10 COSM92048538 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3753G>C p.L1251= 7:89336735-89336735 9
11 COSM92024942 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3661G>C p.A1221P 7:89336643-89336643 9
12 COSM88575001 ZNF804A lung,NS,carcinoma,small cell carcinoma c.862A>T p.K288* 2:184936258-184936258 9
13 COSM88576053 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3281C>T p.S1094F 2:184938677-184938677 9
14 COSM84362584 ZNF777 lung,NS,carcinoma,small cell carcinoma c.1998C>T p.C666= 7:149432274-149432274 9
15 COSM114445791 ZNF746 lung,NS,carcinoma,small cell carcinoma c.890C>T p.A297V 7:149475432-149475432 9
16 COSM97007058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 9
17 COSM97006621 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1509G>T p.E503D 23:85270913-85270913 9
18 COSM110827987 ZNF7 lung,NS,carcinoma,small cell carcinoma c.1022G>C p.G341A 8:144842096-144842096 9
19 COSM122146768 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 9
20 COSM92174992 ZNF660 lung,NS,carcinoma,small cell carcinoma c.575G>A p.C192Y 3:44594768-44594768 9
21 COSM86006104 ZNF653 lung,NS,carcinoma,small cell carcinoma c.808C>T p.P270S 19:11487655-11487655 9
22 COSM86006115 ZNF653 lung,NS,carcinoma,small cell carcinoma c.346C>T p.R116W 19:11496163-11496163 9
23 COSM105713312 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 9
24 COSM109858474 ZNF630 lung,NS,carcinoma,small cell carcinoma c.1534G>C p.E512Q 23:48058908-48058908 9
25 COSM90459483 ZNF609 lung,NS,carcinoma,small cell carcinoma c.1497C>T p.H499= 15:64674351-64674351 9
26 COSM87900489 ZNF608 lung,NS,carcinoma,small cell carcinoma c.3511C>T p.P1171S 5:124646873-124646873 9
27 COSM87898587 ZNF608 lung,NS,carcinoma,small cell carcinoma c.1722G>T p.Q574H 5:124648662-124648662 9
28 COSM87805997 ZNF574 lung,NS,carcinoma,small cell carcinoma c.860C>G p.S287C 19:42079196-42079196 9
29 COSM100923094 ZNF566 lung,NS,carcinoma,small cell carcinoma c.177G>T p.L59F 19:36472969-36472969 9
30 COSM91872428 ZNF536 lung,NS,carcinoma,small cell carcinoma c.1216C>A p.P406T 19:30444778-30444778 9
31 COSM91878766 ZNF536 lung,NS,carcinoma,small cell carcinoma c.3241C>A p.Q1081K 19:30548860-30548860 9
32 COSM91878758 ZNF536 lung,NS,carcinoma,small cell carcinoma c.383G>T p.R128L 19:30443945-30443945 9
33 COSM91871331 ZNF536 lung,NS,carcinoma,small cell carcinoma c.3646C>A p.Q1216K 19:30549265-30549265 9
34 COSM91884888 ZNF536 lung,NS,carcinoma,small cell carcinoma c.2185G>A p.A729T 19:30534861-30534861 9
35 COSM91873317 ZNF536 lung,NS,carcinoma,small cell carcinoma c.2259C>A p.C753* 19:30534935-30534935 9
36 COSM94775928 ZNF521 lung,NS,carcinoma,small cell carcinoma c.3289G>A p.V1097M 18:25224629-25224629 9
37 COSM94775934 ZNF521 lung,NS,carcinoma,small cell carcinoma c.2620G>T p.G874W 18:25225298-25225298 9
38 COSM94778877 ZNF521 lung,NS,carcinoma,small cell carcinoma c.3640G>T p.V1214F 18:25195178-25195178 9
39 COSM94791907 ZNF521 lung,NS,carcinoma,small cell carcinoma c.2227G>T p.V743L 18:25225691-25225691 9
40 COSM94774741 ZNF521 lung,NS,carcinoma,small cell carcinoma c.559G>C p.D187H 18:25227359-25227359 9
41 COSM91637929 ZNF512 lung,NS,carcinoma,small cell carcinoma c.698A>G p.D233G 2:27602491-27602491 9
42 COSM91851364 ZNF507 lung,NS,carcinoma,small cell carcinoma c.1899C>G p.Y633* 19:32354729-32354729 9
43 COSM91851246 ZNF507 lung,NS,carcinoma,small cell carcinoma c.1007C>G p.S336C 19:32353837-32353837 9
44 COSM90068876 ZNF479 lung,NS,carcinoma,small cell carcinoma c.1027C>T p.H343Y 7:57120388-57120388 9
45 COSM87572084 ZNF462 lung,NS,carcinoma,small cell carcinoma c.5136G>T p.L1712= 9:106929048-106929048 9
46 COSM91573770 ZNF444 lung,NS,carcinoma,small cell carcinoma c.239T>A p.V80E 19:56147150-56147150 9
47 COSM137384456 ZNF423 lung,NS,carcinoma,small cell carcinoma c.3329C>A p.P1110H 16:49635823-49635823 9
48 COSM137379733 ZNF423 lung,NS,carcinoma,small cell carcinoma c.1772T>G p.I591S 16:49637380-49637380 9
49 COSM137393174 ZNF423 lung,NS,carcinoma,small cell carcinoma c.146C>A p.T49K 16:49730902-49730902 9
50 COSM151538926 ZNF385B lung,NS,carcinoma,small cell carcinoma c.1381G>T p.A461S 2:179443285-179443285 9

Expression for Lung Non-Squamous Non-Small Cell Carcinoma

Search GEO for disease gene expression data for Lung Non-Squamous Non-Small Cell Carcinoma.

Pathways for Lung Non-Squamous Non-Small Cell Carcinoma

Pathways related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 VEGFA ROS1 KRAS KDR HRAS FLT1
2
Show member pathways
13.73 VEGFA ROS1 KRAS KDR HRAS FLT1
3
Show member pathways
13.58 ROS1 KRAS KDR HRAS FLT1 ERBB2
4
Show member pathways
13.57 VEGFA ROS1 KRAS KDR HRAS FLT1
5
Show member pathways
13.49 PDCD1LG2 PDCD1 KRAS HRAS ERBB2 EGFR
6
Show member pathways
13.44 ROS1 KRAS KDR HRAS FLT1 ERBB2
7
Show member pathways
13.34 ROS1 KRAS KDR HRAS FLT1 ERBB2
8
Show member pathways
13.25 VEGFA ROS1 KRAS KDR HRAS FLT1
9
Show member pathways
13.07 KRAS KDR HRAS FLT1 EGFR ALK
10
Show member pathways
13 VEGFA KRAS KDR HRAS FLT1 ERBB2
11
Show member pathways
12.97 ROS1 KDR FLT1 ERBB2 EGFR ALK
12
Show member pathways
12.91 VEGFA RET KRAS HRAS ERBB2 EGFR
13
Show member pathways
12.91 VEGFA KRAS KDR HRAS FLT1 ERBB2
14 12.78 VEGFA RET KRAS HRAS ERBB2 EML4
15
Show member pathways
12.76 VEGFA KRAS KDR HRAS FLT1 EGFR
16 12.73 VEGFA KRAS KDR HRAS FLT1 ERBB2
17
Show member pathways
12.69 KRAS HRAS ERBB2 EML4 EGFR ALK
18
Show member pathways
12.64 VEGFA KRAS KDR HRAS ERBB2 EGFR
19 12.58 VEGFA KRAS HRAS ERBB2 EGFR
20
Show member pathways
12.51 KRAS KDR HRAS FLT1 ERBB2 EGFR
21
Show member pathways
12.5 VEGFA KRAS KDR HRAS FLT1 EGFR
22
Show member pathways
12.44 KRAS KDR HRAS FLT1 ERBB2 EGFR
23
Show member pathways
12.43 VEGFA KRAS KDR HRAS FLT1 EGFR
24
Show member pathways
12.42 VEGFA KDR HRAS FLT1 EGFR
25
Show member pathways
12.41 VEGFA KRAS KDR HRAS
26
Show member pathways
12.4 PDCD1 KRAS HRAS EML4 EGFR CTLA4
27
Show member pathways
12.35 KRAS HRAS ERBB2 EGFR
28
Show member pathways
12.34 KRAS HRAS ERBB2 EGFR
29
Show member pathways
12.33 VEGFA KRAS HRAS EGFR
30 12.28 VEGFA KRAS KDR HRAS ERBB2 EGFR
31
Show member pathways
12.27 ROS1 KRAS KDR HRAS FLT1 ERBB2
32
Show member pathways
12.25 PDCD1LG2 PDCD1 CTLA4 CD274
33
Show member pathways
12.25 KRAS KDR HRAS FLT1 ERBB2 EGFR
34 12.22 KRAS HRAS ERBB2 EGFR
35
Show member pathways
12.18 KRAS HRAS ERBB2 EGFR
36 12.16 PDCD1LG2 PDCD1 CTLA4 CD274
37
Show member pathways
12.1 KRAS HRAS ERBB2 EGFR
38 11.99 VEGFA FLT1 ERBB2 EGFR
39
Show member pathways
11.99 KRAS HRAS ERBB2 EGFR
40
Show member pathways
11.89 VEGFA KDR HRAS FLT1
41
Show member pathways
11.88 VEGFA ERBB2 EGFR
42 11.88 VEGFA FLT1 CTLA4
43
Show member pathways
11.87 KRAS HRAS EGFR
44 11.85 KRAS HRAS EGFR
45
Show member pathways
11.79 RET KRAS KDR HRAS FLT1
46
Show member pathways
11.74 VEGFA TYMS EGFR
47 11.69 VEGFA KRAS HRAS ERBB2 EGFR
48 11.67 ROS1 RET KDR FLT1 ERBB2 EGFR
49 11.65 RET KRAS HRAS ERBB2 EGFR
50 11.64 KRAS HRAS ERBB2 EGFR

GO Terms for Lung Non-Squamous Non-Small Cell Carcinoma

Cellular components related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10 ROS1 RET PDCD1LG2 PDCD1 MTUS1 KRAS
2 membrane GO:0016020 9.89 VEGFA TYMS ROS1 RET PDCD1LG2 PDCD1
3 integral component of plasma membrane GO:0005887 9.86 ROS1 RET KDR FLT1 ERBB2 EGFR
4 endosome GO:0005768 9.8 RET KDR FLT1 ERBB2 EGFR CD274
5 membrane raft GO:0045121 9.67 RET KRAS KDR EGFR
6 receptor complex GO:0043235 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Biological processes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 VEGFA RET PDCD1LG2 KRAS HRAS ERBB2
2 multicellular organism development GO:0007275 10.11 VEGFA ROS1 RET PDCD1 KDR FLT1
3 phosphorylation GO:0016310 10.09 ROS1 RET KDR FLT1 ERBB2 EGFR
4 protein phosphorylation GO:0006468 10.08 ROS1 RET KDR FLT1 ERBB2 EGFR
5 positive regulation of gene expression GO:0010628 10.05 VEGFA RET KRAS HRAS ERBB2
6 positive regulation of cell proliferation GO:0008284 10.02 VEGFA KRAS KDR HRAS FLT1 ERBB2
7 cell surface receptor signaling pathway GO:0007166 10 PDCD1LG2 HRAS ERBB2 EGFR CD274
8 MAPK cascade GO:0000165 9.96 RET KRAS HRAS ERBB2 EGFR
9 protein autophosphorylation GO:0046777 9.91 KDR FLT1 ERBB2 EGFR ALK
10 positive regulation of cell migration GO:0030335 9.87 VEGFA RET KDR HRAS FLT1 EGFR
11 positive regulation of protein phosphorylation GO:0001934 9.85 VEGFA KRAS KDR HRAS ERBB2 EGFR
12 liver development GO:0001889 9.84 KRAS HRAS EGFR
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.82 VEGFA KDR FLT1
14 positive regulation of epithelial cell proliferation GO:0050679 9.8 VEGFA HRAS ERBB2 EGFR
15 positive regulation of MAPK cascade GO:0043410 9.8 RET KDR HRAS FLT1 ERBB2
16 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ROS1 RET KDR FLT1 ERBB2 EGFR
17 negative regulation of T cell proliferation GO:0042130 9.78 PDCD1LG2 CTLA4 CD274
18 peptidyl-tyrosine autophosphorylation GO:0038083 9.77 ROS1 KDR EGFR
19 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.76 VEGFA KDR FLT1
20 sprouting angiogenesis GO:0002040 9.75 VEGFA KDR FLT1
21 regulation of ERK1 and ERK2 cascade GO:0070372 9.74 ROS1 ERBB2 EGFR
22 T cell costimulation GO:0031295 9.73 PDCD1LG2 PDCD1 CTLA4 CD274
23 vascular endothelial growth factor signaling pathway GO:0038084 9.7 VEGFA KDR FLT1
24 positive regulation of phospholipase C activity GO:0010863 9.67 HRAS FLT1
25 positive regulation of positive chemotaxis GO:0050927 9.66 VEGFA KDR
26 tetrahydrofolate metabolic process GO:0046653 9.65 TYMS DHFR
27 vascular wound healing GO:0061042 9.65 VEGFA KDR
28 response to isolation stress GO:0035900 9.64 KRAS HRAS
29 negative regulation of ERBB signaling pathway GO:1901185 9.63 ERBB2 EGFR
30 tetrahydrofolate biosynthetic process GO:0046654 9.63 GART DHFR
31 positive regulation of MAP kinase activity GO:0043406 9.63 VEGFA KRAS HRAS FLT1 ERBB2 EGFR
32 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 VEGFA KDR
33 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.61 VEGFA KDR
34 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.5 ROS1 RET KDR FLT1 ERBB2 EGFR
35 positive regulation of kinase activity GO:0033674 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Molecular functions related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 10.03 ROS1 RET KDR GART FLT1 ERBB2
2 transferase activity GO:0016740 10.02 TYMS ROS1 RET KDR GART FLT1
3 nucleotide binding GO:0000166 9.9 TYMS ROS1 RET KRAS KDR HRAS
4 kinase activity GO:0016301 9.87 ROS1 RET KDR FLT1 ERBB2 EGFR
5 protein kinase activity GO:0004672 9.8 ROS1 RET KDR FLT1 ERBB2 EGFR
6 protein phosphatase binding GO:0019903 9.67 ROS1 ERBB2 EGFR
7 growth factor binding GO:0019838 9.58 KDR FLT1 ERBB2
8 sequence-specific mRNA binding GO:1990825 9.52 TYMS DHFR
9 folic acid binding GO:0005542 9.51 TYMS DHFR
10 protein tyrosine kinase activity GO:0004713 9.5 ROS1 RET KDR FLT1 ERBB2 EGFR
11 vascular endothelial growth factor binding GO:0038085 9.48 KDR FLT1
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.46 KDR FLT1
13 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.17 ROS1 RET KDR FLT1 ERBB2 EGFR

Sources for Lung Non-Squamous Non-Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....